Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Recombinant Pbp2a As a Vaccine Candidate Against Methicillin-Resistant Staphylococcus Aureus: Immunogenicity and Protectivity Publisher Pubmed



Haghighat S1 ; Siadat SD2 ; Rezayat Sorkhabadi SM3 ; Akhavan Sepahi A4 ; Sadat SM5 ; Yazdi MH6 ; Mahdavi M7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Microbiology, Faculty of Advanced Sciences and Technology, Islamic Azad University (IAUPS), Pharmaceutical Sciences Branch, Tehran, Iran
  2. 2. Department of Mycobacteriology & Pulmonary Research, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
  3. 3. Department of Pharmacology & Toxicology, Faculty of Pharmacy, Islamic Azad University (IAUPS), Pharmaceutical Sciences Branch, Tehran, Iran
  4. 4. Department of Microbiology, Faculty of Basic Sciences, Islamic Azad University, North Tehran Branch, Tehran, Iran
  5. 5. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
  6. 6. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Immunology, Pasteur Institute of Iran, Tehran, Iran

Source: Microbial Pathogenesis Published:2017


Abstract

Methicillin-resistant Staphylococcus aureus infections are focal and development of an effective vaccine can help to control this infection. Here, recombinant PBP2a was studied in mouse model. Following the preparation of recombinant PBP2a, Balb/c mice were injected subcutaneously with 20 μg of r-PBP2a formulated in Freund's adjuvant three times with three weeks intervals with proper control group. Total and specific isotype antibodies were evaluated on sera by ELISA. Opsonophagocytic activity was also investigated on the sera samples. Intraperitonealchallenge with a sub-lethal dose of MRSA (5 × 108 CFU) was done in experimental mice. Following that, the number of bacteria from kidneys of experimental mice were determined. Survival rate was recorded for 60 days. Significant increase of antibody with high level of IgG1, IgG2a and IgG2b isotypes was demonstrated in vaccinated mice versus the control group (P < 0.005). The bacterial load in the kidneys from immunized mice was 1000 times less thancontrol group (PBS) and opsonophagocytic activity of immunized mice sera significantly increased (P < 0.0001). Finally the life span of immunized mice after bacterial challenge was extended versus control mice. These results may indicate the capacity of PBP2a as a candidate vaccine to control the MRSA infections. © 2017
Related Docs
View other Related Docs
1. Recombinant Staphylococcal Antigen-F (R-Scaf), a Novel Vaccine Candidate Against Methicillin Resistant Staphylococcus Aureus Infection: Potency and Efficacy Studies, Microbial Pathogenesis (2019)
2. Recombinant Pbp2a of Methicillin-Resistant S. Aureus Formulation in Alum and Montanide Isa266 Adjuvants Induced Cellular and Humoral Immune Responses With Protection in Balb/C Mice, Microbial Pathogenesis (2020)
3. Passive Immunization Against Methicillin Resistant Staphylococcus Aureus Recombinant Pbp2a in Sepsis Model of Mice: Comparable Results With Antibiotic Therapy, International Immunopharmacology (2018)
4. The Candidate Antigens to Achieving an Effective Vaccine Against Staphylococcus Aureus, Vaccines (2022)
5. Protection of Mice Against Staphylococcus Aureus Infection by a Recombinant Protein Clfa–Isdb–Hlg As a Vaccine Candidate, Medical Microbiology and Immunology (2016)
6. Immunogenicity and Protective Efficacy of Pseudomonas Aeruginosa Type a and B Flagellin Vaccines in a Burned Mouse Model, Molecular Immunology (2016)
7. Killed Whole-Cell Staphylococcus Aureus Formulation in Montanide Isa266 and Alum Adjuvants: Different Vaccine Formulations Varied in the Vaccine’S Potency and Efficacy, Immunologic Research (2025)
8. Passive Immunotherapy With Specific Igg Fraction Against Autolysin: Analogous Protectivity in the Mrsa Infection With Antibiotic Therapy, Immunology Letters (2019)
Experts (# of related papers)
View all Related Experts
Farhad Bonakdar Hashmi (3)
Mohammad Reza Pourmand (2)
Other Related Docs
9. Flagellin and Pilin Immunization Against Multi-Drug Resistant Pseudomonas Aeruginosa Protects Mice in the Burn Wound Sepsis Model, Immunology Letters (2016)
10. Immunological Evaluation of an Alginate-Based Conjugate As a Vaccine Candidate Against Pseudomonas Aeruginosa, APMIS (2015)
11. Epitope-Based Immunoinformatics Study of a Novel Hla-Mntc-Sacol0723 Fusion Protein From Staphylococcus Aureus: Induction of Multi-Pattern Immune Responses, Molecular Immunology (2019)
12. A Trivalent Vaccine Consisting of “Flagellin A+B and Pilin” Protects Against Pseudomonas Aeruginosa Infection in a Murine Burn Model, Microbial Pathogenesis (2020)